Navigation Links
ERT to Present at the Citi 2011 Global Health Care Conference on November 15, 2011
Date:11/7/2011

PHILADELPHIA, Nov. 7, 2011 /PRNewswire/ -- ERT (Nasdaq: ERT), announced today that Dr. Jeffrey S. Litwin, the Company's President and CEO is scheduled to present at the Citi 2011 Global Health Care Conference at 1:00PM PST on Nov. 15, 2011 in Las Vegas.

Interested parties may access the presentation by visiting the Company's corporate website at http://www.ert.com. The webcast may also be accessed at http://www.veracast.com/webcasts/citigroup/smidcap2011/98108111.cfm. The webcast will be available via replay for 90 days.

About ERTERT (www.ert.com) is a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations. It is the market leader for centralized cardiac safety and respiratory efficacy services in drug development and also collects, analyzes and distributes electronic Patient Reported Outcomes (ePRO) in multiple modalities across all phases of clinical research.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of n
'/>"/>

SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting
2. Cantel Medical Corp. to Present at the Stephens Inc. Fall Investment Conference
3. Abaxis, Inc. to Present at Sidoti & Companys New York II Emerging Growth Institutional Investor Forum
4. Caliper CEO Kevin Hrusovsky Presented Vision for Revolutionizing Medicine
5. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
6. Vermillion to Present at Stephens Fall Investment Conference on November 16, 2011
7. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
8. PAREXEL International to Present at Lazard Capital Markets Healthcare Conference and Citi Small/Mid Cap Conference
9. Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD
10. Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011
11. HeartWare to Present at the Credit Suisse 2011 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 RadiologyAuction will have their first ... and product demonstrations at the end of the auction ... as Kodak and Fuji Cr,s, Agfa and Sony, printers ... first event. Various imaging equipment will be available at ... After years of buying and selling imaging equipment, ...
(Date:5/4/2015)... 2015 Rogne Bioscience, a privately-held biotechnology company ... preclinical and mechanism of action data will be presented ... Dermatology (SID) Annual Meeting being held May 6-9, 2015 ... . Logo - http://photos.prnewswire.com/prnh/20150501/213318LOGO ... a novel, low MW (<1700 daltons) peptide as a ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... SINGAPORE , UPPSALA, Sweden and CANTON, Mass. , ... that the US Food and Drug Administration (FDA) has given the ... Mesh, for use in reinforcement of soft tissues where weakness exists. ... synthetic matrix, knitted from two different resorbable fibers that degrade at ...
... SAN FRANCISCO, Calif. , Feb. 5 Poniard Pharmaceuticals, Inc. ... today announced that Ronald Martell , chief executive officer, will provide ... on Tuesday, February 9, 2010 at 1:00 p.m. Eastern ... . , A live audio webcast of the corporate overview will be ...
Cached Medicine Technology:Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh 2Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh 3Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference 2
(Date:5/4/2015)... May 04, 2015 The American ... G. Thomopulos, P.E., Chairman of Stanley Consultants , ... board of directors for a three-year term. , ACEC ... and the American Society of Civil Engineers (ASCE). ... rating system for civil infrastructure called Envision. Launched in ...
(Date:5/4/2015)... 2015 Malibu Biotech Systems LLC ... spray. KissSafe™ is the first personal hygiene product ... while adding fresh breath appeal. KissSafe™ contains an ... germs in the mouth and oral cavity before ... that possess additional wellness benefits. KissSafe’s proprietary prevent-tech ...
(Date:5/4/2015)... Leonardo J. Lozada, M.D., Saint Luke’s Health ... William C. Daniel, M.D., Saint Luke’s Health System chief ... the Secretary of the Air Force to attend the ... War College, Maxwell Air Force Base, Alabama. The purpose ... U.S. and international officers and their civilian counterparts in ...
(Date:5/4/2015)... SACRAMENTO, Calif. (PRWEB) May 04, 2015 ... Permanente Medical Group today launched a new initiative ... building the next generation of physicians committed to ... Estudiantes Para Ser Medicos, or Preparing Students to ... multi-faceted initiative that will provide scholarships, mentorship and ...
(Date:5/4/2015)... New York, New York (PRWEB) May 04, 2015 ... as much as $2.4 billion to settle thousands of ... Type 2 diabetes medication increases the risk that a ... documents issued on April 28th, if 95% of those ... accord will resolve nearly 9,000 bladder cancer cases currently ...
Breaking Medicine News(10 mins):Health News:Thomopulos Appointed to Institute for Sustainable Infrastructure Board 2Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3
... of a two-year clinical trial that Avastin, a drug approved ... to treat age-related macular degeneration (AMD), is as effective as ... of AMD. The report, from the Comparison ... New England Journal of Medicine on Sunday, May ...
... DETROIT A new Henry Ford Hospital study takes a ... most serious side-effects of ACE inhibitor use facial, tongue ... invasive course of treatment. Using a treatment ... and promptly treated to reduce swelling, resulting in no tracheotomies ...
... release is available in French and Spanish ... have proven that melatonin a natural hormone produced by the ... intake of food, improves blood lipid profile as it reduces ... is found in small quantities in some fruits and vegetables ...
... April 28, 2011 The first World Congress of Pediatric ... together the largest and most successful international congregation of pediatric ... Journal of Urology and the Journal of ... at this meeting. The vitality of clinical and ...
... , THURSDAY, April 28 (HealthDay News) -- Women are ... undergoing a common heart imaging test called coronary angiography, a ... contrast dye is used to enhance images of the heart,s ... kidney,s blood vessels to narrow, damaging the organ, explained Dr. ...
... , WEDNESDAY, April 27 (HealthDay News) -- If you suffer a ... severe than having one at any other time of day, a ... happens between 6 a.m. and noon, it is likely to damage ... in the afternoon or evening, the researchers added. "It is ...
Cached Medicine News:Health News:NIH study finds Avastin and Lucentis are equally effective in treating AMD 2Health News:NIH study finds Avastin and Lucentis are equally effective in treating AMD 3Health News:NIH study finds Avastin and Lucentis are equally effective in treating AMD 4Health News:Study targets treatment for serious ACE inhibitor side effect 2Health News:Melatonin might help in controlling weight gain and preventing heart diseases associated with obesity 2Health News:Success of First World Congress of Pediatric Urology underscores increasing importance of specialty 2Health News:Women's Kidneys May Be at Higher Risk After Heart Test 2Health News:Morning Heart Attacks Cause More Damage, Study Finds 2Health News:Morning Heart Attacks Cause More Damage, Study Finds 3
Straight heavy shafts with delicate 7 mm tying platform. Sharp pointed tips for removing fine sutures. Wide serrated handle with polished finish. Overall length 4.1 inches....
Angled 45 degree shafts with 10.5 mm tying and 1 mm of tip crisscross serrated. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.2 inches....
Curved, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Titanium. Straight shafts with 6.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.4 inches....
Medicine Products: